Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...

Schrodinger (SDGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

Schrödinger partners with Novartis for advanced computational drug discovery. Q3 revenue rose 10% in software, though total revenue missed; Schrödinger revised 2024 software guidance. Schrödinger to ...

During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...

Mr. Aklian joins Schrödinger from Certara, where he served as senior vice president, global software sales. In this role, Mr. Aklian led a global team of professionals in sales and operations and ...

Research teams can spend nearly a decade looking for new biological targets, but Schrödinger software is helping researchers drastically decrease those timelines by turning to Amazon Web Services.

Schrödinger, a little-known software company that helps some of the largest pharmaceutical brands with drug discovery, made its public debut. The company closed its initial public offering on Monday, ...

This drug discovery company's stock just took a major hit. Amid wild stock price swings, many wonder if they will be catching a falling knife if they buy shares now. Is Schrodinger a safe investment ...